NEW YORK (GenomeWeb News) – ServiceXS, a genomics and proteomics services firm based in Leiden, the Netherlands, will perform a large-scale genome-wide association study for the European Union’s Melanoma Genetics Consortium, the company said Friday.
ServiceXS said it will use Ilumina’s Infinium multiplex technology to genotype 300,000 tag SNPs in 1,800 subjects for the GenoMEL study.
Candidate SNPs will be validated in a case-control study including 4,000 melanoma cases and 4,000 control individuals, the company said.
Financial terms of the agreement were not released.
Further information about the GenoMEL study is available here.